Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results

Sagimet Biosciences Inc. (NASDAQ:SGMT) earns a place on our list of the top 10 stocks under $5 that could triple.

Analysts Remain Optimistic in Sagimet Biosciences (SGMT)’s Outlook Following Q4 and Full-Year 2025 Results

As of March 19, 2026, 91% of analysts remain bullish on Sagimet Biosciences Inc. (NASDAQ:SGMT). The stock boasts a consensus price target of $27.50, indicating an upside of 437.27%.

On March 11, 2026, in its fourth-quarter and full-year 2025 financial results update, Sagimet Biosciences Inc. (NASDAQ:SGMT) emphasized ongoing pipeline momentum, which strengthened investor confidence. In the second half of 2026, the company plans to commence a Phase 2 trial in F4 MASH patients. This development comes after the company successfully completed a Phase 1 pharmacokinetic trial, assessing denifanstat in combination with resmetirom, with no significant adverse effects.

Its ongoing first-in-human Phase 1 trial for TVB-3567, which targets acne, is another example of Sagimet Biosciences Inc.’s (NASDAQ:SGMT) progress. Additionally, Ascletis, a partner, published positive Phase 3 acne data and obtained NDA acceptance in China.

In terms of finances, Sagimet Biosciences Inc. (NASDAQ:SGMT) concluded 2025 with $113.1 million in cash, $39.1 million in R&D costs, and a $51.0 million net loss as opposed to a $45.6 million loss in 2024.

Importantly, HC Wainwright reaffirmed its “Buy” rating that same day, demonstrating confidence in the stock.

Sagimet Biosciences Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company developing FASN inhibitors, such as denifanstat, to address metabolic and dermatological disorders, particularly for MASH and acne treatments.

While we acknowledge the risk and potential of SGMT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SGMT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.